It’s been a rough start to 2025 for Indian pharmaceutical giants. Four of India’s biggest generic drug producers issued product recalls in the last three months.
In January, Glenmark Pharmaceuticals started things off when they recalled a massive 1.4 million bottles of the attention deficit disorder drug called atomoxetine. Glenmark makes this at its lab in the Arabian Sea coastal city of Goa.
Sun Pharmaceuticals was the second to issue a recall. They recalled 10,000 bottles of the painkiller morphine sulphate extended release tablets on Feb. 6. A week later, Zydus Pharmaceuticals recalled 38,871 vials of the chemotherapy injectable nelarabine. The chemo drug was manufactured at the company’s Ahmedabad, India lab.
More recently, on March 13, Dr. Reddy’s Laboratories recalled around 1,000 levetiracetam infusion bags that had been shipped to the U.S. in November. Levetiracetam is an anti-epileptic medication used primarily to treat seizures.
Read the article.